Why do anti-tumor necrosis factor antibodies work in Crohn's disease?

Rev Gastroenterol Disord. 2004;4 Suppl 3:S10-7.

Abstract

Anti-tumor necrosis factor (TNF) antibodies are powerful therapeutic agents for the treatment of Crohn's disease. TNF has diverse proinflammatory effects within the intestinal mucosa and is a pivotal cytokine in the inflammatory cascade. Although anti-TNF antibodies exert a variety of anti-inflammatory effects by neutralizing the cytokine, these agents vary in their efficacy. Recent data suggest that the ability to bind transmembrane TNF is a key property necessary for efficacy. Transmembrane binding of TNF effects apoptosis of T cells, thereby alleviating a fundamental defect in Crohn's disease in the regulation of T cell populations.

Publication types

  • Review

MeSH terms

  • Animals
  • Antibodies / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Apoptosis / physiology
  • Biological Therapy
  • Certolizumab Pegol
  • Crohn Disease / drug therapy
  • Crohn Disease / immunology
  • Crohn Disease / physiopathology*
  • Etanercept
  • Humans
  • Immunoglobulin Fab Fragments
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Polyethylene Glycols / therapeutic use
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Recombinant Fusion Proteins / therapeutic use
  • T-Lymphocytes / immunology
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors
  • Tumor Necrosis Factor-alpha / immunology*
  • Tumor Necrosis Factor-alpha / physiology

Substances

  • Antibodies
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Immunoglobulin Fab Fragments
  • Immunoglobulin G
  • Receptors, Tumor Necrosis Factor
  • Recombinant Fusion Proteins
  • Tumor Necrosis Factor-alpha
  • CDP 571
  • Polyethylene Glycols
  • Infliximab
  • Etanercept
  • Certolizumab Pegol